Novartis to buy IFM Tre for up to $1.57bn

The deal will provide Novartis with full rights to IFM Tre’s clinical and preclinical anti-inflammatory programmes. Credit: Novartis AG.



  • Novartis to buy IFM Tre for up to $1.57bn